Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call Transcript
Key Points
- Ultragenyx Pharmaceutical Inc (RARE) exceeded its revenue guidance for 2024, showcasing strong financial performance.
- The company successfully launched Evkeeza in Europe, Canada, and Japan, contributing to impressive international growth.
- Ultragenyx is advancing six late-stage programs in serious genetic conditions, with potential for significant value creation.
- The UX111 program for Sanfilippo syndrome shows promising clinical data, potentially leading to the company's first commercial gene therapy product.
- The company is on track for full-year GAAP profitability by 2027, supported by strong global revenue growth and multiple product launches.
- Ultragenyx reported a net loss of $569 million for 2024, highlighting ongoing financial challenges.
- Total operating expenses for the year were $1.1 billion, indicating high costs associated with R&D and SG&A.
- There is expected quarter-to-quarter revenue variability due to uneven ordering patterns for Crysvita in Latin America.
- The company faces risks and uncertainties related to regulatory approvals for its gene therapy programs.
- Ultragenyx's cash used in operations was $414 million in 2024, emphasizing the need for careful expense management.
Good afternoon, and welcome to the Ultragenyx fourth-quarter and full-year 2024 financial results conference call. (Operator Instructions)
It is now my pleasure to turn over the call to Joshua Higa, Vice President of Investor Relations. Please go ahead.
Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer; and Eric Crombez, Chief Medical Officer.
I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.
I'll now turn the call over to Emil.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
